Qiuyun Luo
Shenzhen, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinoma.
Journal: NPJ precision oncology
Published: July 17, 2025
CYP4F11 promotes lung cancer progression through the miR-195/ME2 pathway.
Journal: Frontiers of medicine
Published: April 01, 2025
Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells.
Journal: Cancer cell international
Published: February 22, 2024
The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma.
Journal: International journal of oncology
Published: July 26, 2023
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.
Journal: Cellular & molecular immunology
Published: March 17, 2023
Prediction of Poor Outcomes in Patients with Colorectal Cancer: Elevated Preoperative Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT).
Journal: Cancer management and research
Published: January 20, 2020
Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma.
Journal: Cancer medicine
Published: July 26, 2019
A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma.
Journal: Journal of experimental & clinical cancer research : CR
Published: February 11, 2018
APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells.
Journal: International journal of oncology
Published: February 20, 2017
Showing 1-12 of 12
Last Updated: 09/26/2026